A5056254307- Substance Abuse Treatment and Outcomes
- Bipolar Disorder and Treatment
- Schizophrenia research and treatment
- Sleep and related disorders
- Mental Health Treatment and Access
- Child and Adolescent Psychosocial and Emotional Development
- Long-Term Effects of COVID-19
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Influenza Virus Research Studies
- Cannabis and Cannabinoid Research
- Pathogenesis and Treatment of Hiccups
- Forensic Toxicology and Drug Analysis
- Safety Warnings and Signage
- Electroconvulsive Therapy Studies
- Sleep and Wakefulness Research
- HIV, Drug Use, Sexual Risk
- Opioid Use Disorder Treatment
- COVID-19 and Mental Health
- Homelessness and Social Issues
- User Authentication and Security Systems
- Family Caregiving in Mental Illness
- Intensive Care Unit Cognitive Disorders
- Respiratory viral infections research
- Treatment of Major Depression
- Youth Substance Use and School Attendance
National Institute of Mental Health
2020-2024
Kitakyushu Municipal Medical Center
2024
National Center of Neurology and Psychiatry
2020-2024
Hizen Psychiatric Center
2024
Psychiatric Medical Center
2024
Kitasato University
2009
To examine the clinical characteristics of over-the-counter (OTC) drug abusers in psychiatric practice Japan.
Abstract Aim To investigate changes in the clinical characteristics of patients who abused benzodiazepine receptor agonists (BZRA) or over‐the‐counter (OTC) drugs before and after COVID‐19 based on 2018 2022 data “Nationwide Psychiatric Hospital (NPH) Survey Drug‐related Disorders.” Method A total 446 155 cases, 435 273 mainly BZRAs OTC drugs, respectively, were extracted from database two NPH Surveys. Demographic variables, education, employment, criminal record, drug use during previous...
Hikikomori, a severe form of social withdrawal, is increasingly serious mental health issue worldwide. Hikikomori comorbid with various psychiatric conditions including depression, anxiety and suicidal behaviors. Family support encouraged as vital first step, however evidence-based programs have yet to be established. Mental Health First Aid (MHFA) one the most well-validated educational encouraging lay people such family members, close persons suffering from behaviors.We newly developed an...
This study was carried out to investigate whether the personal advocacy of influenza vaccination by community pharmacists people aged 65 years and above affected rate number patients. A cluster randomized controlled trial conducted with cooperation 84 pharmacies in wards Suginami Nerima, Tokyo. Participants were living Nerima wards, Tokyo, receiving dispensing services their pharmacies. The intervention that pharmacy group provided information on risk benefits vaccination. Main outcome...
Abstract Aim The objective of the current study was to identify risk factors that affect onset dependence and chronic psychosis due cannabis use. Methods We examined clinical genetic factors, psychiatric disorders prior use, starting age duration frequency types products used, combined use other psychoactive substances, diagnosis 71 patients with cannabis‐related who underwent treatment at nine mental health hospitals in Japan. Information collected from cross‐sectional interview surveys...
Introduction Individuals involved with the criminal justice system face challenges in receiving and maintaining substance use disorder (SUD) treatment support. Although telephone monitoring (TM) could reduce these barriers, data on TM for community-dwelling individuals research who drop out of are scarce. We examined factors associated dropping early from Voice Bridges Project, which provides probation drug-related convictions through community mental health centers Japan. Methods...
Pharmacotherapy is generally the first choice for treatment of acute mania in bipolar disorder. Electroconvulsive therapy (ECT) reported to be an effective modality mania; however, it usually used as "last resort." Herein, we report a case patient with treatment-resistant severe disorder who recovered ECT without concurrent antipsychotics and mood stabilizers. Our showed that monotherapy can manic state disorder, which may lead shorter hospital stay better social outcomes.
ラモトリギンは,2008年12月に他の抗てんかん薬で十分な効果が認められないてんかん患者に対する抗てんかん薬との併用療法，2011年7月に双極性障害における気分エピソードの再発・再燃抑制に対して適応となり,当院では2009年9月より採用された。本論文では双極性障害に対する適応が認められた2011年7月から2014年7月31日までの当院におけるラモトリギン処方例総数177例（男性51例，女性126例）について後方視的にカルテを参照し解析した。全体の平均年齢は45.5歳である。96例が双極性障害（Ⅰ型32例，Ⅱ型64例）の診断であった。継続例が97例，中止例が80例で，中止例80例の主な中止理由としては「病状不変のため」であった。皮疹による中止は22例あった。継続例97例のうち76例（80％）は病状改善を認めている。ラモトリギンは双極性障害のうつ病相，維持療法における治療薬として有用である。